Non-Hodgkin Lymphoma Therapeutics Market - Historic Data (2019-2024), Global Trends 2025, Growth Forecasts 2037
Non-Hodgkin Lymphoma Therapeutics Market in 2025 is estimated at USD 10.7 billion. The global Market size was valued at more than USD 10.07 billion in 2024 and is expected to register a CAGR of over 7.8%, exceeding USD 26.73 billion revenue by 2037. North America is forecast to record USD 8.02 billion by 2037, fueled by advancements in AI and healthcare technologies.
The market’s growth is attributed to the increasing prevalence of non-hodgkin lymphoma. During the past few years, the world has witnessed a significant surge in the non-hodgkin lymphoma.
As per our survey, non-hodgkin lymphoma is amongst the most common hematological malignancy across the globe and accounts for about 3% of cancer deaths and diagnoses. Further, according to the American Cancer Society, there will be roughly 80,620 NHL diagnoses in 2024 (44,590 men and 36,030 women). This applies to both kids and adults.
Furthermore, there has been surge in research in this field in order to deal with the growing cases. For instance, Researchers funded by the NCI are improving our knowledge of lymphoma treatment. The lymph system, that's a component of the body's immune system, is the place where all lymphomas begin. Scientists are now able to create more individualized treatments for different subtypes of lymphoma owing to advances in understanding the gene alterations that might cause the disease. All this is leading to non-Hodgkin lymphoma therapeutics market growth.
Non- Hodgkin Lymphoma Therapeutics Sector: Growth Drivers and Challenges
Growth Drivers
- Surge in geriatric population - According to the World Health Organization, one in six individuals globe are going to be 60 years of age or older by 2030. This will culminate in a rise in the proportion of people over 60 from 1 billion in 2020 to 1.4 billion at this point. At a median age of 67 years at diagnosis, non-hodgkin lymphoma (NHL) mostly impacts older persons.
Adults with NHL who are older may find treatment difficult. A decrease in functional reserve that is unique to each person as they age raises the possibility of treatment-related toxicity and death. Furthermore, the primary determinant of a patient's survival following a cancer diagnosis is their age. As a result, the demand for non-Hodgkin Lymphoma market is rising.
- Increasing health awareness amongst people - People are becoming more conscious of their health, which leads to expectations that medicines will experience higher demand in near future. A number of health awareness programs are being organized by governments of various countries across the globe. The market is anticipated to respond in tandem with the novel drug introductions for the treatment of ovarian cancer. Various researchers are investing in the introduction of market-beneficial medications. More opportunities in the market result from this.
- Rising number of R&D initiatives - Owing to the increased occurrence of these types of lymphomas, the non-hodgkin lymphoma therapeutics market is currently seeing the introduction of sophisticated products. Many significant market participants, both well-known and up-and-coming, have made investments in the creation of pipeline candidates and the introduction of new drugs.
The high number of patients with these tumors, who frequently need intensive and precise therapy because their symptoms don't show up, is the reason for the rising demand. Despite advanced diagnostics, the diagnosis of cancer in its latter stages is frequently made due to the absence of symptoms. Throughout the forecast period, this is anticipated to further fuel the market expansion for non-hodgkin lymphoma therapeutics. Therefore, the demand for more sophisticated treatments has resulted in rising R&D trends in the market.
Challenges
- Limited Access to Treatment - The fact that most patients globally lack access to therapy is one of the biggest issues facing the sector. Almost every licensed medications for the treatment of non-hodgkin lymphoma are available in the majority of North American and European countries.
However, with developing and poor economies, there are few therapeutic choices available for the treatment of diseases. Although non-hodgkin lymphoma and other blood malignancies are highly prevalent in these nations, patients find it challenging to receive treatment on time due to a lack of available therapeutic alternatives.
- Lack of efficient healthcare technology may hinder the non-hodgkin lymphoma therapeutics market’s revenue.
- High cost of approved therapies - The prevalence of various blood malignancies, including lymphomas, has sharply increased, and these trends have also been seen in a number of developing nations. The high cost of some medicines, like immunotherapies, is one of the main obstacles to the expansion of the non-Hodgkin lymphoma therapeutics market.
This drastically limits the number of patients receiving complex and advanced care, and a sizable fraction of lymphoma patients are not receiving any treatment at all. Patients frequently cannot take advantage of these cutting-edge treatment choices, which frequently lead to superior clinical outcomes, because of inadequate payment plans and special considerations from the local governments.
Non-Hodgkin Lymphoma Therapeutics Market: Key Insights
| Report Attribute | Details |
|---|---|
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
7.8% |
|
Base Year Market Size (2024) |
USD 10.07 billion |
|
Forecast Year Market Size (2037) |
USD 26.73 billion |
|
Regional Scope |
|
Non-Hodgkin Lymphoma Therapeutics Segmentation
Type of Therapy (Chemotherapy, Radiation Therapy, Target Therapy)
The chemotherapy segment in the non-Hodgkin lymphoma therapeutics market is estimated to gain the largest revenue share of about 50% in the year 2037. Chemotherapy is a highly effective treatment for cancer since it stops the cancer cells from spreading more and increasingly widely. It is the most used cancer treatment, working to stop the growth of tumors and eliminate cancer cells. Furthermore, chemotherapy continues to be a mainstay since it works for a wide range of NHL subtypes, despite the advent of new therapies.
The fact that healthcare practitioners are familiar with it and its well-established protocols add to its ongoing demand. Furthermore, chemotherapy is frequently a financially advantageous course of treatment in areas with limited resources. In light of these aspects non-hodgkin lymphoma market is predicted to expand in this segment.
Distribution Channel (Retail Pharmacies & Drug Stores, Hospital Pharmacies, Online Pharmacies)
The hospital pharmacies segment is expected to hold 50% share of the global non-Hodgkin lymphoma therapeutics market by 2037. The non-hodgkin lymphoma therapies market is dominated by the hospital pharmacy segment for a number of reasons. Major cancer treatment facilities include hospitals, which offer complete care, including diagnosis, therapy, and follow-up.
The efficient distribution and administration of several medicines are made possible by this focused strategy. Hospitals are also equipped with the facilities needed to handle and store specialized treatments like targeted therapies and chemotherapy. Further, owing to rising number of hospitals the non-hodgkin lymphoma therapeutics market will flourish. The overall number of hospitals globally as of 2021 is estimated to be over 164,000.
Our in-depth analysis of the global non-Hodgkin lymphoma therapeutics market includes the following segments:
|
Type of Therapy |
|
|
Cell Type |
|
|
Distribution Channel |
|
Vishnu Nair
Head - Global Business DevelopmentCustomize this report to your requirements — connect with our consultant for personalized insights and options.
Non-Hodgkin Lymphoma Therapeutics Industry - Regional Synopsis
North American Market Statistics
Non-hodgkin lymphoma therapeutics market in the North America industry is likely to account for largest revenue share of 30% by 2037. This growth is set to be dominated by growing advancement and adoption of latest technology such as AI. For instance, in the areas of radiology, neurology, and pathology, the Food & Drug Administration (FDA) in the United States will have assessed and authorized over 500 medical AI devices by 2023.
Artificial intelligence (AI) has become so popular in the last few years that a lot of money has been spent on its development and commercialization in the medical industry. Furthermore, there has been launch of various well-regulated framework which has influenced the launch of various treatment options in the region. Also, since the healthcare sector is one of the most regulated in the US, healthcare compliance is an important and rapidly expanding field within the sector. Hence, all these factors are set to dominate the non-hodgkin lymphoma therapeutics market expansion in this region.
APAC Market Analysis
The Asia Pacific non-Hodgkin lymphoma therapeutics market is also estimated to rise over the coming years. The major element to encourage the growth of the market in this region is rising demand for generic manufacturers. Furthermore, generic drugs are considered to be most affordable.
Hence, with the availability of low-income group the market demand for generic drug is more in this region. Further, the quality of these drugs is same of that branded drugs which is why the demand for it is high. As a result, the rising need for generic drug the market for non-hodgkin lymphoma therapeutics is also set to rise in this region.
Companies Dominating the Non-Hodgkin Lymphoma Therapeutics Market
- AbbVie, Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Teva Pharmaceutical Industries Ltd.
- Sanofi
- Pfizer Inc.
- GSK plc.
- Novartis AG
- Bayer AG
- Bausch Health Companies Inc.
- Sun Pharmaceutical Industries Ltd.
- Aurobindo Pharma
- SIRPant Immunotherapeutics Inc.
Recent Developments
- SIRPant-M's investigational new drug (IND) application got FDA approval in May 2023 after reviewing preclinical data that indicated the medication was effective against a range of solid tumours as well as hematologic tumours.
- AbbVie announced that EPKINLYTM (epcoritamab-bysp), the first and only T-cell engaging bispecific antibody, has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with high-grade B-cell lymphoma (HGBL) and diffuse large B-cell lymphoma (DLBCL) that have undergone two or more lines of systemic therapy and are relapsed or refractory (R/R).
- Report ID: 5584
- Published Date: May 09, 2025
- Report Format: PDF, PPT
- Get detailed insights on specific segments/region
- Inquire about report customization for your industry
- Learn about our special pricing for startups
- Request a demo of the report’s key findings
- Understand the report’s forecasting methodology
- Inquire about post-purchase support and updates
- Ask About Company-Level Intelligence Additions
Have specific data needs or budget constraints?
Inquiry Before BuyingFrequently Asked Questions (FAQ)
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Connect with our Expert
